Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

AXSM

Axsome Therapeutics Inc

Feb 11 • 10:59AM ET

182.03

-2.27 -1.23 %

Healthcare • Biotechnology • USA • NASD

Peers: BIIB ACAD VRTX ALKS NBIX BHVN SAGE PRTA AVDL RARE

| Held by: VTI IWM VB VBK VXF IWO IBB SCHA VTWO IHE

Index	RUT	P/E	-	EPS (ttm)	-4.67	Insider Own	17.73%	Shs Outstand	50.31M	Perf Week	-1.89%
Market Cap	9.18B	Forward P/E	281.24	EPS next Y	0.65	Insider Trans	-7.78%	Shs Float	41.48M	Perf Month	2.95%
Enterprise Value	9.07B	PEG	-	EPS next Q	-0.69	Inst Own	74.70%	Short Float	6.54%	Perf Quarter	32.10%
Income	-229.53M	P/S	16.35	EPS this Y	37.26%	Inst Trans	0.09%	Short Ratio	4.16	Perf Half Y	72.98%
Sales	561.26M	P/B	124.21	EPS next Y	117.22%	ROA	-37.30%	Short Interest	2.71M	Perf YTD	-0.33%
Book/sh	1.47	P/C	28.21	EPS next 5Y	-	ROE	-275.50%	52W High	191.50 -4.95%	Perf Year	37.69%
Cash/sh	6.45	P/FCF	-	EPS past 3/5Y	-20.03% -24.44%	ROIC	-104.76%	52W Low	86.99 109.25%	Perf 3Y	189.90%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	90.31%	Volatility	2.76% 3.09%	Perf 5Y	146.99%
Dividend TTM	-	EV/Sales	16.16	EPS Y/Y TTM	28.50%	Oper. Margin	-34.71%	ATR (14)	5.43	Perf 10Y	2557.37%
Dividend Ex-Date	-	Quick Ratio	1.50	Sales Y/Y TTM	65.83%	Profit Margin	-40.89%	RSI (14)	55.28	Recom	1.14
Dividend Gr. 3/5Y	- -	Current Ratio	1.57	EPS Q/Q	29.64%	SMA20	-0.91%	Beta	0.41	Target Price	215.44
Payout	-	Debt/Eq	2.96	Sales Q/Q	63.22%	SMA50	8.77%	Rel Volume	0.38	Prev Close	184.30
Employees	683	LT Debt/Eq	1.97	Earnings	Feb 23 BMO	SMA200	40.54%	Avg Volume	651.90K	Price	182.03
IPO	Nov 19, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	-9.15% 5.11%	Trades		Volume	66,048	Change	-1.23%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-08-26	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$204
Oct-01-25	Initiated	B. Riley Securities	Buy	$179
Sep-03-25	Resumed	Wells Fargo	Overweight	$163
Jul-03-25	Resumed	Morgan Stanley	Overweight	$190
Jun-03-25	Initiated	Oppenheimer	Outperform	$185
Apr-07-25	Initiated	Jefferies	Buy	$200
Feb-11-25	Initiated	Deutsche Bank	Buy	$176
Dec-31-24	Reiterated	Mizuho	Outperform	$124 → $122
Sep-03-24	Initiated	Wells Fargo	Overweight	$140
Aug-06-24	Upgrade	BofA Securities	Neutral → Buy	$95 → $106
Jul-22-24	Initiated	Needham	Buy	$130
Apr-29-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$90 → $115
Mar-19-24	Initiated	Robert W. Baird	Outperform	$108
Feb-06-24	Initiated	UBS	Buy	$111
Jan-25-24	Initiated	RBC Capital Mkts	Outperform	$126
Dec-13-23	Initiated	Citigroup	Buy	$125
Aug-08-23	Upgrade	BofA Securities	Underperform → Neutral	$59 → $81
Jan-05-23	Initiated	Piper Sandler	Neutral	$75
Nov-01-22	Initiated	Loop Capital	Buy	$95
Sep-07-22	Resumed	Mizuho	Buy	$49 → $76

Show Previous Ratings

Feb-03-26 12:05PM	1 High-Flying Stock With More Upside Ahead (Motley Fool)
06:55AM	Axsome Therapeutics (AXSM) Reports 66% Revenue Growth in FY2025, Beats Analyst Estimates (Insider Monkey)
Jan-27-26 07:00AM	Axsome Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 23 (GlobeNewswire)
Jan-26-26 10:15AM	Auvelity Continues to Aid AXSM's Top Line: More Upside in 2026? (Zacks)
Jan-23-26 12:01AM	Top Picks 2026- Axsome Therapeutics Inc. AXSM (MoneyShow)
09:52PM	Loading…
Jan-22-26 09:52PM	Piper Sandler Bullish on Axsome Therapeutics (AXSM) Ahead of Likely Auvelity Label Expansion by April 30 (Insider Monkey)
Jan-21-26 08:18AM	Strength Seen in Axsome (AXSM): Can Its 4.1% Jump Turn into More Strength? (Zacks)
Jan-16-26 11:15AM	Axsome Therapeutics Begins Phase III Study on AXS-14 for Fibromyalgia (Zacks)
Jan-15-26 09:50AM	Why Axsome Therapeutics (AXSM) is a Top Momentum Stock for the Long-Term (Zacks)
07:00AM	Axsome Therapeutics Initiates FORWARD Phase 3 Trial of AXS-14 for the Management of Fibromyalgia (GlobeNewswire)
Jan-12-26 08:25AM	Axsome Therapeutics Preliminary Q4 Net Product Revenue Up 65% (RTT News)
07:00AM	Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue (GlobeNewswire)
Jan-09-26 11:40AM	HALO or AXSM: Which Is the Better Value Stock Right Now? (Zacks)
Jan-08-26 08:23AM	Biotech Is Heating Up-These 2 Red-Hot Stocks Stand Out (MarketBeat)
05:35AM	2 Healthcare Stocks to Buy for 2026 and Beyond (Motley Fool)
10:54AM	Loading…
Jan-02-26 10:54AM	AXSM Up on FDA Priority Review to AXS-05 sNDA in Alzheimer's Agitation (Zacks)
08:30AM	Axsome (AXSM) Stock Jumps 22.8%: Will It Continue to Soar? (Zacks)
Dec-31-25 12:32PM	Why Axsome Therapeutics Stock Rocketed Higher to End 2025 (Motley Fool) +22.75%
12:18PM	Axsome Therapeutics Stock Jumps After FDA Grants Priority Review For Alzheimer's Agitation Drug (Investor's Business Daily)
11:32AM	Pharma Stock Soars to Record Highs on FDA Buzz (Schaeffer's Research)
10:08AM	Market Movers: Nike Exploding Higher on Insider Buying (24/7 Wall St.)
07:00AM	Axsome Therapeutics Announces FDA Acceptance and Priority Review of Supplemental New Drug Application for AXS-05 for the Treatment of Alzheimer's Disease Agitation (GlobeNewswire)
06:55AM	Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-12 in Narcolepsy Supporting NDA Submission (GlobeNewswire)
Dec-03-25 11:30AM	Axsome (AXSM) Up 5.3% Since Last Earnings Report: Can It Continue? (Zacks)
Dec-01-25 08:06PM	2 Under-the-Radar Stocks to Buy Heading Into 2026 (Motley Fool)
Nov-20-25 07:00AM	Axsome Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-10-25 04:45AM	2 Monster Stocks in the Making (Motley Fool)
Nov-06-25 07:00AM	Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy (GlobeNewswire)
Nov-05-25 02:13PM	Axsome Therapeutics Stock In A Buy Zone. Analysts See Profit On The Horizon. (Investor's Business Daily)
Nov-04-25 10:28AM	AXSM Q3 Loss Wider Than Expected, Revenues Surge Y/Y on Auvelity Sales (Zacks)
02:01PM	Loading…
Nov-03-25 02:01PM	Axsome Therapeutics Inc (AXSM) Q3 2025 Earnings Call Highlights: Robust Revenue Growth and ... (GuruFocus.com)
07:14AM	Axsome: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Axsome Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Oct-28-25 10:00AM	uniQure (QURE) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-27-25 10:00AM	Axsome Therapeutics (AXSM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Oct-24-25 11:20AM	Halper Sadeh LLC Encourages Axsome Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights (Business Wire)
Oct-22-25 07:00AM	Axsome Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-09-25 07:00AM	Axsome Therapeutics Recognizes Mental Illness Awareness Week Along with the National Advocacy Community (GlobeNewswire)
Oct-07-25 07:00AM	Axsome Therapeutics to Report Third Quarter 2025 Financial Results on November 3 (GlobeNewswire)
Oct-02-25 01:35AM	Piper Sandler Maintains Overweight on Axsome (AXSM), Sees Growth in AD-Agitation (Insider Monkey)
Sep-30-25 09:45AM	Can Auvelity Drive Axsome's Growth Through the Rest of 2025? (Zacks)
04:10AM	Prediction: These 2 Under-the-Radar Stocks Could Beat the Market in the Next 5 Years (Motley Fool)
Sep-17-25 07:00AM	Axsome Therapeutics Highlights Data Across Its Leading Neuroscience Pipeline at Psych Congress 2025 (GlobeNewswire)
Sep-09-25 01:07PM	Axsome Therapeutics Stock Sees RS Rating Rise To 82 (Investor's Business Daily)
Sep-04-25 09:00AM	Prediction: These 2 Biotech Stocks Could Double in the Next 5 Years (Motley Fool)
Sep-03-25 11:30AM	Why Is Axsome (AXSM) Up 19.2% Since Last Earnings Report? (Zacks)
Sep-02-25 01:05AM	H.C. Wainwright Reaffirms Buy on Axsome (AXSM) Following Generic Challenge to Portfolio (Insider Monkey)
Aug-29-25 12:27PM	Axsome Shares Up 20% in a Month: How Should You Play the Stock? (Zacks)
Aug-27-25 07:00AM	Axsome Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-21-25 06:55PM	ReAlta Life Sciences Secures European Orphan Drug Status for Graft-vs-Host Disease Treatment (Exec Edge)
Aug-05-25 11:36AM	AXSM Q2 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y (Zacks)
03:09AM	Axsome Therapeutics Inc (AXSM) Q2 2025 Earnings Call Highlights: Robust Revenue Growth and ... (GuruFocus.com)
Aug-04-25 09:30AM	Here's What Key Metrics Tell Us About Axsome (AXSM) Q2 Earnings (Zacks)
08:10AM	Axsome Therapeutics (AXSM) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
07:12AM	Axsome: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Axsome Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Aug-03-25 02:00PM	Palantir, Advanced Micro, Walt Disney, Pfizer, ZoomInfo, and More Stocks to Watch This Week (Barrons.com)
Jul-30-25 07:30AM	2 Growth Stocks Wall Street Predicts Will Soar 74% to 159% (Barchart)
Jul-29-25 10:00AM	Amgen (AMGN) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Jul-28-25 10:00AM	Axsome Therapeutics (AXSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Jul-24-25 05:51AM	2 Top Stocks I Wouldn't Hesitate to Invest $1,000 in Right Now (Motley Fool)
Jul-22-25 09:39AM	ALKS Down Despite Positive Top-Line Data From Narcolepsy Study (Zacks) -6.50%
Jul-21-25 07:30AM	Axsome Therapeutics Hosts Frontiers in Brain Health R&D Day Reviewing Industry-Leading Late-Stage CNS Pipeline (GlobeNewswire)
07:00AM	Axsome Therapeutics to Ring the NASDAQ Stock Market Opening Bell Today (GlobeNewswire)
Jul-09-25 07:00AM	Axsome Therapeutics to Report Second Quarter 2025 Financial Results on August 4 (GlobeNewswire)
Jul-07-25 07:00AM	Axsome Therapeutics to Showcase Its Innovative CNS Pipeline at Upcoming Frontiers in Brain Health R&D Day in New York City on July 21 (GlobeNewswire)
Jul-06-25 04:15AM	Morgan Stanley Assumes Coverage of Axsome Therapeutics (AXSM) with an Overweight Rating (Insider Monkey)
Jul-04-25 07:48AM	Here's Why Harmony Biosciences Is an Unconventional Cannabis Investment (Zacks)
03:23AM	Piper Sandler Reaffirms Price Target on Axsome (AXSM) Despite AXS-14 FDA Hurdle (Insider Monkey)
Jun-20-25 07:00AM	Axsome Therapeutics Champions Brain Health During Alzheimer's & Brain Awareness Month (GlobeNewswire)
Jun-18-25 07:00AM	Axsome Therapeutics to Present Data Spanning the SYMBRAVO (meloxicam and rizatriptan) Clinical Program at the 67th Annual Scientific Meeting of the American Headache Society (AHS) (GlobeNewswire)
Jun-16-25 07:00AM	Axsome Therapeutics Proudly Supports Migraine and Headache Awareness Month Alongside the Association of Migraine Disorders (GlobeNewswire)
Jun-11-25 07:57PM	Axsome's AXS-14 Gets Regulatory Setback with RTF, says Morgan Stanley (Insider Monkey)
07:00AM	Axsome Therapeutics Showcases Innovation in Sleep Medicine with Multiple Presentations for AXS-12 and Solriamfetol at SLEEP 2025 (GlobeNewswire)
Jun-10-25 07:00AM	Axsome Therapeutics Announces Availability of SYMBRAVO (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults (GlobeNewswire)
Jun-09-25 07:00AM	Axsome Therapeutics Provides Update on the New Drug Application (NDA) for AXS-14 for the Management of Fibromyalgia (GlobeNewswire)
Jun-05-25 03:19AM	2 Soaring Stocks Wth More Upside Potential (Motley Fool)
Jun-04-25 11:30AM	Why Is Axsome (AXSM) Down 1.8% Since Last Earnings Report? (Zacks)
May-29-25 07:00AM	Axsome Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-28-25 07:00AM	Axsome Therapeutics Presents Data from Three of Its Innovative Neuroscience Programs at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting (GlobeNewswire)
May-27-25 07:00AM	Axsome Therapeutics Settles SUNOSI (solriamfetol) Patent Litigation with Hetero Labs Ltd. (GlobeNewswire)
May-24-25 06:40AM	3 High-Flying Stocks That Could Soar Even More (Motley Fool)
May-14-25 07:30PM	Is Axsome Therapeutics Stock Worth the Risk? A Comprehensive Analysis (Motley Fool)
May-13-25 07:00AM	Axsome Therapeutics Enters $570 Million Term Loan and Revolving Credit Facility with Blackstone (GlobeNewswire)
May-12-25 07:08AM	Prediction: These 2 Stocks Will Outperform the Market in the Next Five Years (Motley Fool)
May-11-25 11:15AM	3 Monster Stocks in the Making (Motley Fool)
May-06-25 09:39AM	AXSM Q1 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y (Zacks)
03:02AM	Axsome Therapeutics Inc (AXSM) Q1 2025 Earnings Call Highlights: Robust Revenue Growth and ... (GuruFocus.com)
12:24AM	Q1 2025 Axsome Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
May-05-25 11:44AM	Axsome Therapeutics, Inc. (AXSM) Q1 2025 Earnings Call Transcript (Seeking Alpha)
09:30AM	Axsome (AXSM) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
08:15AM	Axsome Therapeutics (AXSM) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Axsome Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-01-25 07:00AM	Axsome Therapeutics and Mental Health America (MHA) Join Voices to Highlight Mental Health Month (GlobeNewswire)
Apr-30-25 10:01AM	TG Therapeutics (TGTX) to Report Q1 Results: Wall Street Expects Earnings Growth (Zacks)
Apr-28-25 10:00AM	Earnings Preview: Axsome Therapeutics (AXSM) Q1 Earnings Expected to Decline (Zacks)
Apr-22-25 07:00AM	Axsome Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Apr-10-25 09:52AM	Axsome (AXSM) Moves 4.2% Higher: Will This Strength Last? (Zacks) -5.92%
06:18AM	Seeking Recession-Proof Stocks? RBC Suggests 2 Healthcare Stocks to Buy (TipRanks)
Apr-08-25 07:00AM	Axsome Therapeutics to Report First Quarter 2025 Financial Results on May 5 (GlobeNewswire)

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Coleman Mark	Director	Feb 10 '26	Option Exercise	8.02	5,193	41,648	53,405	Feb 10 07:11 PM
TABUTEAU HERRIOT	Chief Executive Officer	Feb 02 '26	Option Exercise	8.02	32,410	259,928	39,639	Feb 02 06:30 PM
TABUTEAU HERRIOT	Chief Executive Officer	Feb 02 '26	Sale	185.60	32,410	6,015,296	7,229	Feb 02 06:30 PM
Herriot Tabuteau	Officer	Feb 02 '26	Proposed Sale	185.88	32,410	6,024,371		Feb 02 05:30 PM
Pizzie Nick	Chief Financial Officer	Jan 22 '26	Option Exercise	3.50	12,000	42,000	54,588	Jan 23 07:00 PM
Pizzie Nick	Chief Financial Officer	Jan 22 '26	Sale	187.92	12,000	2,255,040	42,588	Jan 23 07:00 PM
Maizel Ari	Chief Commercial Officer	Jan 21 '26	Option Exercise	70.73	7,500	530,475	7,500	Jan 23 07:00 PM
Maizel Ari	Chief Commercial Officer	Jan 21 '26	Sale	184.44	7,500	1,383,300	0	Jan 23 07:00 PM
Pizzie Nick	Officer	Jan 22 '26	Proposed Sale	187.92	12,000	2,254,989		Jan 22 04:02 PM
Maizel Ari	Officer	Jan 21 '26	Proposed Sale	184.44	7,500	1,383,327		Jan 21 04:08 PM
TABUTEAU HERRIOT	Chief Executive Officer	Jan 05 '26	Option Exercise	8.02	78,703	631,198	85,932	Jan 07 07:00 PM
TABUTEAU HERRIOT	Chief Executive Officer	Jan 07 '26	Option Exercise	8.02	31,261	250,713	38,490	Jan 07 07:00 PM
TABUTEAU HERRIOT	Chief Executive Officer	Jan 06 '26	Option Exercise	8.02	29,450	236,189	36,679	Jan 07 07:00 PM
TABUTEAU HERRIOT	Chief Executive Officer	Jan 05 '26	Sale	171.28	78,703	13,480,250	7,229	Jan 07 07:00 PM
TABUTEAU HERRIOT	Chief Executive Officer	Jan 07 '26	Sale	170.38	31,261	5,326,249	7,229	Jan 07 07:00 PM
TABUTEAU HERRIOT	Chief Executive Officer	Jan 06 '26	Sale	172.33	29,450	5,075,118	7,229	Jan 07 07:00 PM
Herriot Tabuteau	Officer	Jan 07 '26	Proposed Sale	170.69	31,261	5,335,940		Jan 07 04:44 PM
Herriot Tabuteau	Officer	Jan 06 '26	Proposed Sale	171.88	29,450	5,061,866		Jan 06 04:58 PM
Herriot Tabuteau	Officer	Jan 05 '26	Proposed Sale	171.49	78,703	13,496,777		Jan 05 05:18 PM
Saad Mark E	Director	Dec 31 '25	Option Exercise	5.46	37,577	205,135	41,348	Jan 02 07:02 PM
Saad Mark E	Director	Dec 31 '25	Sale	165.18	37,577	6,206,969	10,002	Jan 02 07:02 PM
Saad Mark E	Director	Dec 31 '25	Proposed Sale	165.18	37,577	6,206,927		Dec 31 04:00 PM
TABUTEAU HERRIOT	Chief Executive Officer	Dec 02 '25	Option Exercise	8.02	49,252	395,001	56,481	Dec 04 07:39 PM
TABUTEAU HERRIOT	Chief Executive Officer	Dec 03 '25	Option Exercise	8.02	20,163	161,707	27,392	Dec 04 07:39 PM
TABUTEAU HERRIOT	Chief Executive Officer	Dec 04 '25	Option Exercise	8.02	10,558	84,675	17,787	Dec 04 07:39 PM
TABUTEAU HERRIOT	Chief Executive Officer	Dec 02 '25	Sale	144.59	49,252	7,121,347	7,229	Dec 04 07:39 PM
TABUTEAU HERRIOT	Chief Executive Officer	Dec 03 '25	Sale	146.94	20,163	2,962,751	7,229	Dec 04 07:39 PM
TABUTEAU HERRIOT	Chief Executive Officer	Dec 04 '25	Sale	148.18	10,558	1,564,484	7,229	Dec 04 07:39 PM
Herriot Tabuteau	Officer	Dec 04 '25	Proposed Sale	148.04	10,558	1,563,006		Dec 04 05:11 PM
Herriot Tabuteau	Officer	Dec 03 '25	Proposed Sale	147.81	20,163	2,980,293		Dec 03 05:58 PM
Herriot Tabuteau	Officer	Dec 02 '25	Proposed Sale	142.09	49,252	6,998,217		Dec 02 05:14 PM
Herriot Tabuteau	Officer	Nov 05 '25	Proposed Sale	135.69	21,775	2,954,650		Nov 05 07:19 PM
TABUTEAU HERRIOT	Chief Executive Officer	Nov 03 '25	Option Exercise	8.02	91,705	735,474	98,934	Nov 05 07:01 PM
TABUTEAU HERRIOT	Chief Executive Officer	Nov 04 '25	Option Exercise	8.02	50,459	404,681	57,688	Nov 05 07:01 PM
TABUTEAU HERRIOT	Chief Executive Officer	Nov 05 '25	Option Exercise	8.02	21,775	174,636	29,004	Nov 05 07:01 PM
TABUTEAU HERRIOT	Chief Executive Officer	Nov 03 '25	Sale	132.34	91,705	12,136,240	7,229	Nov 05 07:01 PM
TABUTEAU HERRIOT	Chief Executive Officer	Nov 04 '25	Sale	133.79	50,459	6,750,910	7,229	Nov 05 07:01 PM
TABUTEAU HERRIOT	Chief Executive Officer	Nov 05 '25	Sale	134.49	21,775	2,928,520	7,229	Nov 05 07:01 PM
Herriot Tabuteau	Officer	Nov 04 '25	Proposed Sale	134.93	50,459	6,808,433		Nov 04 05:47 PM
Herriot Tabuteau	Officer	Nov 03 '25	Proposed Sale	135.75	91,705	12,448,954		Nov 03 05:56 PM
TABUTEAU HERRIOT	Chief Executive Officer	Oct 06 '25	Option Exercise	8.02	19,220	154,144	26,449	Oct 08 09:08 PM
TABUTEAU HERRIOT	Chief Executive Officer	Oct 07 '25	Option Exercise	8.02	13,390	107,388	20,619	Oct 08 09:08 PM
TABUTEAU HERRIOT	Chief Executive Officer	Oct 08 '25	Option Exercise	8.02	12,774	102,447	20,003	Oct 08 09:08 PM
TABUTEAU HERRIOT	Chief Executive Officer	Oct 06 '25	Sale	120.17	19,220	2,309,667	7,229	Oct 08 09:08 PM
TABUTEAU HERRIOT	Chief Executive Officer	Oct 07 '25	Sale	118.77	13,390	1,590,330	7,229	Oct 08 09:08 PM
TABUTEAU HERRIOT	Chief Executive Officer	Oct 08 '25	Sale	118.84	12,774	1,518,062	7,229	Oct 08 09:08 PM
Herriot Tabuteau	Officer	Oct 08 '25	Proposed Sale	118.71	12,774	1,516,402		Oct 08 04:54 PM
Herriot Tabuteau	Officer	Oct 07 '25	Proposed Sale	118.64	13,390	1,588,590		Oct 07 04:43 PM
Herriot Tabuteau	Officer	Oct 06 '25	Proposed Sale	119.94	19,220	2,305,247		Oct 06 04:47 PM
Jacobson Mark L.	Chief Operating Officer	Sep 22 '25	Option Exercise	2.85	10,000	28,500	10,000	Sep 22 07:00 PM
Jacobson Mark L.	Chief Operating Officer	Sep 22 '25	Sale	115.96	10,000	1,159,600	0	Sep 22 07:00 PM
Jacobson Mark L.	Officer	Sep 22 '25	Proposed Sale	115.96	10,000	1,159,571		Sep 22 04:13 PM
Jacobson Mark L.	Chief Operating Officer	Sep 16 '25	Option Exercise	4.91	40,000	196,500	40,000	Sep 17 07:00 PM
Jacobson Mark L.	Chief Operating Officer	Sep 16 '25	Sale	114.48	45,783	5,241,127	0	Sep 17 07:00 PM
TABUTEAU HERRIOT	Chief Executive Officer	Sep 12 '25	Option Exercise	8.02	27,907	223,814	35,136	Sep 16 07:36 PM
TABUTEAU HERRIOT	Chief Executive Officer	Sep 16 '25	Option Exercise	8.02	19,719	158,146	26,948	Sep 16 07:36 PM
TABUTEAU HERRIOT	Chief Executive Officer	Sep 15 '25	Option Exercise	8.02	15,254	122,337	22,483	Sep 16 07:36 PM
TABUTEAU HERRIOT	Chief Executive Officer	Sep 12 '25	Sale	118.96	27,907	3,319,817	7,229	Sep 16 07:36 PM
TABUTEAU HERRIOT	Chief Executive Officer	Sep 16 '25	Sale	114.19	19,719	2,251,713	7,229	Sep 16 07:36 PM
TABUTEAU HERRIOT	Chief Executive Officer	Sep 15 '25	Sale	117.37	15,254	1,790,362	7,229	Sep 16 07:36 PM
Jacobson Mark L.	Officer	Sep 16 '25	Proposed Sale	114.48	45,783	5,241,305		Sep 16 05:39 PM
Herriot Tabuteau	Officer	Sep 16 '25	Proposed Sale	114.10	19,719	2,249,938		Sep 16 04:47 PM
Herriot Tabuteau	Officer	Sep 15 '25	Proposed Sale	116.78	15,254	1,781,286		Sep 15 06:35 PM
Herriot Tabuteau	Officer	Sep 12 '25	Proposed Sale	118.42	27,907	3,304,747		Sep 12 07:19 PM
Coleman Mark	Director	Sep 08 '25	Buy	127.28	1,575	200,466	48,212	Sep 09 08:11 PM
Saad Mark E	Director	Sep 05 '25	Option Exercise	9.00	9,127	82,143	19,129	Sep 05 07:43 PM
Saad Mark E	Director	Sep 05 '25	Sale	125.07	9,127	1,141,514	10,002	Sep 05 07:43 PM
Saad Mark E	Director	Sep 05 '25	Proposed Sale	125.07	9,127	1,141,529		Sep 05 05:08 PM
JEFFS ROGER	Director	Sep 02 '25	Sale	123.68	13,464	1,665,228	57,510	Sep 02 07:11 PM
JEFFS ROGER	Director	Sep 02 '25	Proposed Sale	123.68	13,464	1,665,162		Sep 02 04:01 PM
JEFFS ROGER	Director	Aug 27 '25	Sale	122.30	20,000	2,446,000	110,974	Aug 29 07:08 PM
JEFFS ROGER	Director	Aug 28 '25	Sale	121.60	20,000	2,432,000	90,974	Aug 29 07:08 PM
JEFFS ROGER	Director	Aug 29 '25	Sale	121.27	20,000	2,425,400	70,974	Aug 29 07:08 PM
JEFFS ROGER	Director	Aug 29 '25	Proposed Sale	121.27	20,000	2,425,335		Aug 29 04:02 PM
JEFFS ROGER	Director	Aug 28 '25	Proposed Sale	121.60	20,000	2,432,004		Aug 28 04:04 PM
JEFFS ROGER	Director	Aug 27 '25	Proposed Sale	122.30	20,000	2,446,052		Aug 27 04:12 PM
JEFFS ROGER	Director	Aug 26 '25	Sale	120.03	20,000	2,400,600	130,974	Aug 26 07:00 PM
JEFFS ROGER	Director	Aug 22 '25	Sale	120.08	16,694	2,004,616	150,974	Aug 26 07:00 PM
JEFFS ROGER	Director	Aug 26 '25	Proposed Sale	120.03	20,000	2,400,658		Aug 26 04:08 PM
JEFFS ROGER	Director	Aug 22 '25	Proposed Sale	120.08	16,694	2,004,598		Aug 22 04:28 PM
Murdock Hunter R.	General Counsel	Jun 20 '25	Option Exercise	29.91	7,500	224,325	7,500	Jun 23 07:42 PM
Murdock Hunter R.	General Counsel	Jun 23 '25	Option Exercise	29.91	6,014	179,879	6,014	Jun 23 07:42 PM
Murdock Hunter R.	General Counsel	Jun 20 '25	Sale	102.47	7,500	768,525	0	Jun 23 07:42 PM
Murdock Hunter R.	General Counsel	Jun 23 '25	Sale	100.12	6,014	602,122	0	Jun 23 07:42 PM
Murdock Hunter R.	Officer	Jun 23 '25	Proposed Sale	100.12	6,014	602,101		Jun 23 04:01 PM
Murdock Hunter R.	Officer	Jun 20 '25	Proposed Sale	102.47	7,500	768,503		Jun 20 04:08 PM
Murdock Hunter R.	General Counsel	Jun 18 '25	Option Exercise	29.91	7,500	224,325	7,500	Jun 18 09:16 PM
Murdock Hunter R.	General Counsel	Jun 16 '25	Option Exercise	29.91	7,500	224,325	7,500	Jun 18 09:16 PM
Murdock Hunter R.	General Counsel	Jun 17 '25	Option Exercise	29.91	7,500	224,325	7,500	Jun 18 09:16 PM
Murdock Hunter R.	General Counsel	Jun 16 '25	Sale	102.42	7,500	768,150	0	Jun 18 09:16 PM
Murdock Hunter R.	General Counsel	Jun 18 '25	Sale	100.90	7,500	756,750	0	Jun 18 09:16 PM
Murdock Hunter R.	General Counsel	Jun 17 '25	Sale	100.26	7,500	751,950	0	Jun 18 09:16 PM
Murdock Hunter R.	Officer	Jun 18 '25	Proposed Sale	100.90	7,500	756,729		Jun 18 04:42 PM
Murdock Hunter R.	Officer	Jun 17 '25	Proposed Sale	100.26	7,500	751,975		Jun 17 04:01 PM
Murdock Hunter R.	Officer	Jun 16 '25	Proposed Sale	102.42	7,500	768,154		Jun 16 04:17 PM
Jacobson Mark L.	Chief Operating Officer	Jun 09 '25	Option Exercise	8.02	25,000	200,500	30,783	Jun 10 07:00 PM
Jacobson Mark L.	Chief Operating Officer	Jun 09 '25	Sale	110.44	25,000	2,761,000	5,783	Jun 10 07:00 PM
Jacobson Mark L.	Officer	Jun 09 '25	Proposed Sale	110.44	25,000	2,760,894		Jun 09 04:07 PM
Coleman Mark	Director	May 27 '25	Sale	105.47	3,750	395,512	50,387	May 29 07:00 PM
Coleman Mark	Director	May 28 '25	Sale	103.43	3,750	387,862	46,637	May 29 07:00 PM

Open in Screener

LQDA

Liquidia Corp

Feb 11 • 10:59AM ET

39.65

-0.89 -2.18 %

Healthcare • Biotechnology • USA • NASD

Peers: REGN VRTX ALNY SRPT NBIX ARWR IONS RGEN MDGL XNCR

| Held by: VTI IWM VXF IWO PJP SCHA VTWO KOMP IHE IWC

Index	RUT	P/E	-	EPS (ttm)	-1.43	Insider Own	17.65%	Shs Outstand	86.82M	Perf Week	-10.75%
Market Cap	3.45B	Forward P/E	19.82	EPS next Y	2.00	Insider Trans	-7.69%	Shs Float	71.64M	Perf Month	8.35%
Enterprise Value	3.49B	PEG	-	EPS next Q	0.19	Inst Own	71.89%	Short Float	17.84%	Perf Quarter	45.47%
Income	-121.85M	P/S	49.84	EPS this Y	56.79%	Inst Trans	0.19%	Short Ratio	7.17	Perf Half Y	64.54%
Sales	69.22M	P/B	156.12	EPS next Y	378.99%	ROA	-46.08%	Short Interest	12.78M	Perf YTD	14.98%
Book/sh	0.25	P/C	21.90	EPS next 5Y	-	ROE	-183.82%	52W High	46.67 -15.03%	Perf Year	143.88%
Cash/sh	1.81	P/FCF	-	EPS past 3/5Y	-33.51% 8.44%	ROIC	-73.96%	52W Low	11.26 252.18%	Perf 3Y	477.22%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-3.36% 11.64%	Gross Margin	87.62%	Volatility	7.23% 7.24%	Perf 5Y	1135.36%
Dividend TTM	-	EV/Sales	50.44	EPS Y/Y TTM	11.91%	Oper. Margin	-154.98%	ATR (14)	2.60	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.96	Sales Y/Y TTM	343.41%	Profit Margin	-176.04%	RSI (14)	48.99	Recom	1.44
Dividend Gr. 3/5Y	- -	Current Ratio	2.20	EPS Q/Q	86.17%	SMA20	-4.70%	Beta	0.48	Target Price	45.67
Payout	-	Debt/Eq	9.03	Sales Q/Q	1121.72%	SMA50	7.24%	Rel Volume	0.79	Prev Close	40.54
Employees	157	LT Debt/Eq	6.47	Earnings	Nov 03 BMO	SMA200	59.08%	Avg Volume	1.78M	Price	39.65
IPO	Jul 26, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	89.73% 188.24%	Trades		Volume	373,444	Change	-2.18%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-20-25	Initiated	Wells Fargo	Overweight	$31
Aug-15-25	Resumed	Jefferies	Buy	$43
May-19-25	Downgrade	Oppenheimer	Perform → Underperform	$13
Dec-20-24	Initiated	Wells Fargo	Overweight	$20
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Aug-19-24	Upgrade	Raymond James	Outperform → Strong Buy
Aug-16-24	Initiated	Raymond James	Outperform	$27
Jun-25-24	Initiated	Oppenheimer	Perform
Jan-05-24	Reiterated	Needham	Buy	$18 → $28
Sep-19-22	Resumed	Wedbush	Underperform	$3
Sep-01-22	Downgrade	Wedbush	Neutral → Underperform	$3
Jul-22-22	Initiated	Ladenburg Thalmann	Buy	$15
May-31-22	Initiated	BTIG Research	Buy	$14
May-26-22	Initiated	BofA Securities	Buy	$12
Dec-04-20	Initiated	H.C. Wainwright	Buy	$6
Nov-20-20	Downgrade	Wedbush	Outperform → Neutral	$20 → $4
Nov-08-18	Resumed	Jefferies	Buy
Sep-05-18	Initiated	Wedbush	Outperform	$26
Aug-20-18	Initiated	Needham	Buy	$30
Aug-20-18	Initiated	Jefferies	Buy	$22

Show Previous Ratings

Jan-27-26 08:30AM	Liquidia to Present Clinical Data Across Its Portfolio at the Pulmonary Vascular Research Institute 2026 Annual Congress (GlobeNewswire)
Jan-16-26 08:29AM	Laughing Water Capital's Updates on Liquidia Corp (LQDA) (Insider Monkey)
Jan-15-26 12:00PM	Liquidia Corporation (LQDA) is a Great Momentum Stock: Should You Buy? (Zacks)
Jan-09-26 07:09PM	Why Liquidia Stock Rocked the Market Today (Motley Fool) +12.91%
06:30AM	Liquidia Corporation Announces Preliminary Full-Year 2025 YUTREPIA Net Sales and Corporate Update (GlobeNewswire)
11:40AM	Loading…
Jan-08-26 11:40AM	HRMY vs. LQDA: Which Stock Is the Better Value Option? (Zacks)
Jan-07-26 07:00AM	Liquidia Corporation to Present at 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-15-25 09:06AM	Take the Zacks Approach to Beat the Markets: Liquidia, Western Digital & Johnson & Johnson in Focus (Zacks)
Dec-11-25 09:22AM	Arquitos Capital Management's Updates on Liquidia Corporation (LQDA) (Insider Monkey)
Nov-24-25 09:55AM	Wall Street Analysts See a 51.15% Upside in Liquidia Corporation (LQDA): Can the Stock Really Move This High? (Zacks)
Nov-21-25 12:04PM	United Therapeutics Stock, Up 72% Since August, Nears Buy Point Of Rare Base (Investor's Business Daily)
Nov-16-25 10:14PM	Raymond James Remains Bullish on Liquidia (LQDA), Cites YUTREPIA's 75% Growth in U.S. Prostacyclin Revenue (Insider Monkey)
Nov-06-25 09:55AM	Wall Street Analysts Think Liquidia Corporation (LQDA) Could Surge 62.34%: Read This Before Placing a Bet (Zacks)
Nov-05-25 06:39AM	Liquidia (LQDA) Climbs 10.7%, Nears 52-Week High on Strong Demand for Heart Treatment (Insider Monkey) -5.34%
Nov-03-25 04:02PM	Liquidia Corp (LQDA) Q3 2025 Earnings Call Highlights: Strong YUTREPIA Sales Drive Positive ... (GuruFocus.com) +10.67%
08:00AM	Loading…
08:00AM	Liquidia Corporation to Present at Upcoming Healthcare Investment Conferences (GlobeNewswire)
06:30AM	Liquidia Corporation Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-31-25 09:21AM	Liquidia Corp (LQDA) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Oct-29-25 04:14PM	United Therapeutics Rockets 10% On Growing Enthusiasm For Its Top Drug (Investor's Business Daily)
09:55AM	The Mixed Results For United Therapeutics' Bread-And-Butter Drug (Investor's Business Daily)
Oct-28-25 10:00AM	Niagen Bioscience (NAGE) Reports Next Week: What to Expect (Zacks)
09:35AM	Arcutis Biotherapeutics, Inc. (ARQT) Q3 Earnings and Revenues Surpass Estimates (Zacks)
Oct-27-25 08:30AM	Liquidia Corporation to Report Third Quarter 2025 Financial Results on November 3, 2025 (GlobeNewswire)
Oct-21-25 09:55AM	Wall Street Analysts Believe LIQUIDIA CORP (LQDA) Could Rally 50.94%: Here's is How to Trade (Zacks)
Oct-16-25 04:33PM	BofA Securities Raises Liquidia Corporation (LQDA) PT to $37, Reiterates Buy Rating (Insider Monkey)
Oct-07-25 06:30AM	Liquidia Corporation to Host R&D Day in New York City on October 28, 2025 (GlobeNewswire) +5.10%
Oct-01-25 10:40AM	Is IPF the Next Big Market Opportunity for United Therapeutics? (Zacks)
Sep-29-25 08:30AM	Liquidia to Present Clinical Data from ASCENT Trial at the CHEST 2025 Annual Meeting (GlobeNewswire)
Sep-24-25 04:06AM	Liquidia Corporation (LQDA) Presents Strategic Overview at Well Fargo's Annual Healthcare Conference 2025 (Insider Monkey)
Sep-23-25 10:32AM	Is it a Wise Move to Buy Liquidia Corp. (LQDA) Shares? (Insider Monkey)
02:15PM	Loading…
Sep-16-25 02:15PM	Liquidia Corporation (LQDA): A Bull Case Theory (Insider Monkey)
Sep-11-25 08:30AM	Liquidia Announces Poster Presentations at the Pulmonary Hypertension Professional Association (PHPN) Symposium (GlobeNewswire)
Sep-04-25 01:14PM	Jefferies Highlights Yutrepia's Market Edge in Supporting a Buy on Liquidia (LQDA) (Insider Monkey)
Sep-03-25 01:48PM	UTHR Stock Hits Record High on Tyvaso Meeting IPF Study Goals (Zacks)
Sep-02-25 04:09PM	Why United Therapeutics Catapulted 33%, Pulling Insmed, Liquidia With It (Investor's Business Daily)
09:34AM	Why United Therapeutics Just Catapulted 35%, Pulling Insmed, Liquidia With It (Investor's Business Daily)
Sep-01-25 01:04AM	BTIG Raises Price Target for Liquidia (LQDA), Keeps Buy Rating (Insider Monkey)
Aug-27-25 08:30AM	Liquidia Corporation to Present at the 2025 Wells Fargo Healthcare Conference (GlobeNewswire)
Aug-18-25 11:40PM	Court Victory and Fresh Funding Propel Growth at Liquidia Corporation (Insider Monkey) +6.82%
Aug-13-25 12:54PM	Liquidia (LQDA) Climbs 13.68% as Yutrepia Prescriptions Surge (Insider Monkey)
03:08AM	Liquidia Corp (LQDA) Q2 2025 Earnings Call Highlights: Strong YUTREPIA Launch and Financial Position (GuruFocus.com)
Aug-12-25 04:06PM	Liquidia Shoots Higher As Yutrepia Launch Kicks Off Amid United Patent Battle (Investor's Business Daily) +13.68%
03:00PM	Liquidia Technologies, Inc. (LQDA) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
10:00AM	Liquidia Shoots Higher, But At-Risk Launch Could Come Back To Haunt It (Investor's Business Daily)
06:30AM	Liquidia Corporation Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-11-25 09:22AM	Earnings To Watch: Liquidia Corp (LQDA) Reports Q2 2025 Result (GuruFocus.com)
Aug-05-25 08:30AM	Liquidia Corporation to Report Second Quarter 2025 Financial Results on August 12, 2025 (GlobeNewswire)
Jul-31-25 09:15AM	Vericel Corporation (VCEL) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
Jul-24-25 08:00AM	Insmed Is Trading At A 25-Year High. Will Its 'Skeleton Key' Work? (Investor's Business Daily) +5.75%
Jul-15-25 01:08PM	Liquidia Stock Gets Relative Strength Rating Lift (Investor's Business Daily)
08:59AM	Liquidia Receives $50M from HCRx, Accelerates YUTREPIA's Commercial Launch Following Favorable Court Ruling (Insider Monkey)
Jun-23-25 04:34PM	Liquidia Receives $50 Million from Healthcare Royalty (HCRx) Following First Commercial Sale of YUTREPIA (GlobeNewswire)
Jun-11-25 11:04AM	Insmed Stock Jumps 29% on Encouraging PAH Study Results (Zacks) -5.67%
Jun-10-25 04:07PM	Insmed Catapults Into Breakout Territory On A 'Home Run' For Its Rival To United, Liquidia (Investor's Business Daily) -16.87%
Jun-02-25 06:30AM	Liquidia Schedules First Commercial Shipment of YUTREPIA (treprostinil) Inhalation Powder for Patients with PAH and PH-ILD (GlobeNewswire) +13.07%
May-28-25 08:00AM	Liquidia Corporation to Present at the 2025 Jefferies Global Healthcare Conference (GlobeNewswire) -9.13%
May-24-25 10:47AM	FDA Approves Liquidia Corporation (LQDA)'s YUTREPIA Amid Patent Dispute (Insider Monkey)
May-23-25 02:28PM	U.S. FDA Approves Liquidia's YUTREPIA (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) (GlobeNewswire)
May-12-25 06:00AM	Liquidia Corporation Provides Update on Litigation Filed by United Therapeutics (GlobeNewswire)
May-09-25 03:21AM	Liquidia Corp (LQDA) Q1 2025 Earnings Call Highlights: Strategic Advances and Legal Wins Propel ... (GuruFocus.com)
May-08-25 11:06AM	Buckley Capital's Views on Liquidia Corp. (LQDA) (Insider Monkey)
07:45AM	Liquidia Technologies, Inc. (LQDA) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
06:30AM	Liquidia Corporation Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
May-07-25 06:35PM	Merus N.V. (MRUS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
06:00PM	Here are the major earnings before the open tomorrow (Seeking Alpha)
11:16AM	Liquidia Q1 2025 Earnings Preview (Seeking Alpha)
10:15AM	Earnings To Watch: Liquidia Corp (LQDA) Reports Q1 2025 Result (GuruFocus.com)
May-06-25 08:00AM	Liquidia Corporation to Present at BofA Securities 2025 Health Care Conference (GlobeNewswire)
May-05-25 04:06PM	Liquidia Corporation: A Strong Buy On High Likelihood Of FDA Approval This Month (Seeking Alpha)
09:50AM	Liquidia Technologies (LQDA) Surges 13.2%: Is This an Indication of Further Gains? (Zacks)
May-02-25 05:28PM	District Court Dismisses Dispute Filed by United Therapeutics Against Liquidia (GlobeNewswire) +13.23%
May-01-25 08:00AM	Liquidia Corporation to Report First Quarter 2025 Financial Results on May 8, 2025 (GlobeNewswire)
Apr-30-25 09:30AM	Arquitos Capital's Largest Holdings For Q1 2025 (Seeking Alpha)
Apr-29-25 07:40AM	Regeneron (REGN) Lags Q1 Earnings and Revenue Estimates (Zacks) -5.06%
05:16AM	Urogen Pharma (URGN) Moves 14.1% Higher: Will This Strength Last? (Zacks)
Apr-25-25 06:30AM	Arquitos Capital Management Q1 2025 Investor Letter (Seeking Alpha)
Apr-07-25 06:38AM	Liquidia: United Therapeutics Has The Last Laugh (Seeking Alpha)
Apr-01-25 10:33AM	UPDATE Liquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
08:00AM	Liquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-28-25 09:30AM	Liquidia Corporation Announces FDA Acceptance of New Drug Application Resubmission for YUTREPIA (treprostinil) Inhalation Powder (GlobeNewswire)
Mar-27-25 08:00AM	Liquidia Announces Poster Presentations at the American Thoracic Society (ATS) 2025 International Conference (GlobeNewswire)
Mar-21-25 06:23PM	Earnings To Watch: Liquidia Corp (LQDA) Reports Q4 2024 Result (GuruFocus.com)
Mar-20-25 01:01AM	Q4 2024 Liquidia Corp Earnings Call (Thomson Reuters StreetEvents)
Mar-19-25 11:56AM	Liquidia Corporation (LQDA) Q4 2024 Earnings Call Transcript (SeekingAlpha)
07:45AM	Liquidia Technologies, Inc. (LQDA) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
06:30AM	Liquidia Corporation Reports Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-18-25 08:00AM	Liquidia Corporation Strengthens Financial Position by Amending HealthCare Royalty Agreement to Incrementally Add Up to $100 Million (GlobeNewswire)
Mar-12-25 08:00AM	Liquidia Corporation to Report Full Year 2024 Financial Results on March 19, 2025 (GlobeNewswire)
Feb-24-25 07:00AM	Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors (GlobeNewswire)
Jan-22-25 09:12AM	Liquidia Technologies (LQDA) Moves 5.7% Higher: Will This Strength Last? (Zacks)
Jan-08-25 08:00AM	Liquidia Corporation to Present at 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-27-24 07:11PM	Jim Cramer's Hidden Gem: Why Liquidia Corporation (LQDA) Is the Undervalued Stock You Need to Know (Insider Monkey)
Dec-12-24 10:00AM	Heres Arquitos Capital Managements Updates on Liquidia (LQDA) (Insider Monkey)
09:55AM	Does Liquidia Technologies (LQDA) Have the Potential to Rally 132.54% as Wall Street Analysts Expect? (Zacks)
Nov-26-24 09:55AM	Wall Street Analysts See a 126.13% Upside in Liquidia Technologies (LQDA): Can the Stock Really Move This High? (Zacks)
Nov-14-24 02:09AM	Liquidia Corp (LQDA) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst Regulatory ... (GuruFocus.com)
Nov-13-24 07:40AM	Liquidia Technologies, Inc. (LQDA) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
06:30AM	Liquidia Corporation Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-12-24 08:00AM	Liquidia to Present at the Stifel 2024 Healthcare Conference (GlobeNewswire)
Nov-08-24 07:04AM	Earnings To Watch: Liquidia Corp (LQDA) Reports Q3 2024 Result (GuruFocus.com)

Liquidia Corp. operates as a holding company which engages through its subsidiary in developing and commercializing biopharmaceutical products and novel products development used in PRINT technology to transform the lives of patients. The company was founded in June 2004 and is headquartered in Morrisville, NC.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Boyle Dana	Chief Accounting Officer	Jan 26 '26	Sale	41.65	1,580	65,807	178,848	Jan 28 04:30 PM
Adair Jason	Chief Business Officer	Jan 26 '26	Sale	41.65	688	28,655	211,169	Jan 28 04:30 PM
Krepp Sarah	Chief Human Resource Officer	Jan 12 '26	Sale	37.43	13,165	492,766	140,769	Jan 13 04:36 PM
Moomaw Scott	Chief Commercial Officer	Jan 12 '26	Sale	37.43	20,533	768,550	154,514	Jan 13 04:36 PM
Kaseta Michael	CFO and COO	Jan 12 '26	Sale	37.43	36,932	1,382,365	350,919	Jan 13 04:34 PM
Adair Jason	Chief Business Officer	Jan 12 '26	Sale	37.43	13,548	507,102	184,174	Jan 13 04:34 PM
Schundler Russell	General Counsel	Jan 12 '26	Sale	37.43	27,289	1,021,427	579,394	Jan 13 04:33 PM
JEFFS ROGER	Chief Executive Officer	Jan 12 '26	Sale	37.43	66,610	2,493,212	1,037,528	Jan 13 04:33 PM
Boyle Dana	Chief Accounting Officer	Jan 12 '26	Sale	37.43	11,047	413,489	156,700	Jan 13 04:31 PM
Saggar Rajeev	Chief Medical Officer	Jan 12 '26	Sale	37.43	21,142	791,345	176,883	Jan 13 04:31 PM
Schundler Russell	General Counsel	Dec 01 '25	Sale	32.19	1,072	34,508	577,288	Dec 02 04:34 PM
Krepp Sarah	Chief Human Resource Officer	Dec 01 '25	Sale	32.19	221	7,114	141,218	Dec 02 04:33 PM
Kaseta Michael	CFO and COO	Dec 01 '25	Sale	32.19	1,166	37,534	353,823	Dec 02 04:32 PM
Boyle Dana	Chief Accounting Officer	Dec 01 '25	Sale	32.19	303	9,754	155,031	Dec 02 04:31 PM
Adair Jason	Chief Business Officer	Dec 01 '25	Sale	32.19	693	22,308	175,868	Dec 02 04:31 PM
Moomaw Scott	Chief Commercial Officer	Dec 01 '25	Sale	32.19	831	26,750	154,506	Dec 02 04:30 PM
Adair Jason	Chief Business Officer	Nov 18 '25	Option Exercise	5.89	35,656	210,014	210,654	Nov 20 04:30 PM
Adair Jason	Chief Business Officer	Nov 18 '25	Sale	30.03	35,656	1,070,710	174,998	Nov 20 04:30 PM
JASON ADAIR	Officer	Nov 18 '25	Proposed Sale	28.40	35,656	1,012,630		Nov 18 04:23 PM
Boyle Dana	Chief Accounting Officer	Nov 07 '25	Sale	25.09	29,004	727,674	155,334	Nov 12 04:30 PM
Saggar Rajeev	Chief Medical Officer	Nov 05 '25	Sale	27.00	71,381	1,927,287	176,549	Nov 07 04:30 PM
Dana Boyle	Officer	Nov 07 '25	Proposed Sale	25.09	29,004	727,581		Nov 07 04:07 PM
Rajeev Saggar	Officer	Nov 05 '25	Proposed Sale	27.00	71,381	1,927,287		Nov 05 04:03 PM
Adair Jason	Chief Business Officer	Oct 27 '25	Sale	22.93	692	15,868	174,998	Oct 29 04:30 PM
Boyle Dana	Chief Accounting Officer	Oct 27 '25	Sale	22.93	1,073	24,604	184,338	Oct 29 04:30 PM
Schundler Russell	General Counsel	Oct 13 '25	Sale	23.41	7,839	183,511	576,017	Oct 15 04:36 PM
Kaseta Michael	CFO and COO	Oct 13 '25	Sale	23.41	11,630	272,258	352,646	Oct 15 04:34 PM
Moomaw Scott	Chief Commercial Officer	Oct 13 '25	Sale	23.41	4,900	114,709	153,462	Oct 15 04:34 PM
Saggar Rajeev	Chief Medical Officer	Oct 13 '25	Sale	23.41	5,327	124,705	247,930	Oct 15 04:33 PM
Boyle Dana	Chief Accounting Officer	Oct 13 '25	Sale	23.41	1,238	28,982	185,411	Oct 15 04:32 PM
JEFFS ROGER	Chief Executive Officer	Oct 13 '25	Sale	23.41	20,261	474,310	1,032,973	Oct 15 04:31 PM
Adair Jason	Chief Business Officer	Oct 13 '25	Sale	23.41	3,670	85,915	175,690	Oct 15 04:31 PM
Krepp Sarah	Chief Human Resource Officer	Oct 13 '25	Sale	23.41	1,691	39,586	141,439	Oct 15 04:30 PM
SINGH RAMAN	Director	Sep 15 '25	Option Exercise	2.55	45,524	115,865	76,779	Sep 17 04:30 PM
SINGH RAMAN	Director	Sep 15 '25	Sale	25.81	45,524	1,174,974	31,255	Sep 17 04:30 PM
RAMANDEEP SINGH	Director	Sep 15 '25	Proposed Sale	25.81	45,524	1,175,043		Sep 15 04:02 PM
SINGH RAMAN	Director	Sep 03 '25	Sale	29.42	7,500	220,650	31,255	Sep 05 04:30 PM
Singh Raman	Director	Sep 03 '25	Proposed Sale	29.42	7,500	220,650		Sep 03 04:34 PM
Moomaw Scott	Chief Commercial Officer	Sep 02 '25	Sale	28.63	70,692	2,023,671	155,254	Sep 03 04:33 PM
Schundler Russell	General Counsel	Sep 02 '25	Sale	29.05	1,063	30,880	580,098	Sep 03 04:33 PM
Krepp Sarah	Chief Human Resource Officer	Aug 29 '25	Sale	29.05	209	6,071	143,130	Sep 03 04:32 PM
Kaseta Michael	CFO and COO	Sep 02 '25	Sale	29.05	1,148	33,349	358,448	Sep 03 04:31 PM
Boyle Dana	Chief Accounting Officer	Aug 29 '25	Sale	29.05	296	8,599	186,649	Sep 03 04:30 PM
Manning Paul B	Director	Sep 02 '25	Sale	28.78	328,268	9,446,332	430,828	Sep 02 07:46 PM
Manning Paul B	Director	Aug 29 '25	Sale	27.62	188,232	5,198,968	759,096	Sep 02 07:46 PM
Manning Paul B	Director	Aug 28 '25	Sale	27.94	154,337	4,312,176	947,328	Sep 02 07:46 PM
Adair Jason	Chief Business Officer	Aug 28 '25	Sale	27.86	26,057	725,854	171,029	Sep 02 05:03 PM
Adair Jason	Chief Business Officer	Sep 02 '25	Sale	29.05	451	13,102	172,980	Sep 02 05:03 PM
Saggar Rajeev	Chief Medical Officer	Aug 28 '25	Sale	27.85	20,000	557,072	249,727	Sep 02 05:02 PM
SCOTT MOOMAW	Officer	Sep 02 '25	Proposed Sale	27.68	70,000	1,937,600		Sep 02 04:31 PM
Manning Paul B	Director	Aug 29 '25	Proposed Sale	27.60	947,328	26,146,253		Aug 29 04:18 PM
RAJEEV SAGGAR	Officer	Aug 28 '25	Proposed Sale	28.00	20,000	560,000		Aug 28 04:23 PM
JASON ADAIR	Officer	Aug 28 '25	Proposed Sale	28.00	26,057	729,596		Aug 28 04:19 PM
Manning Paul B	Director	Aug 28 '25	Proposed Sale	27.94	154,337	4,312,469		Aug 28 04:11 PM
Horobin Joanna	Director	Aug 19 '25	Sale	27.17	5,000	135,850	33,755	Aug 21 04:30 PM
Horobin Joanna	Director	Aug 19 '25	Proposed Sale	27.17	5,000	135,850		Aug 19 07:28 PM
Kaseta Michael	CFO and COO	Aug 15 '25	Sale	26.18	20,000	523,674	356,412	Aug 19 04:30 PM
Kaseta Michael	CFO and COO	Aug 05 '25	Sale	20.00	30,000	600,132	376,412	Aug 07 04:30 PM
MICHAEL KASETA	Officer	Aug 05 '25	Proposed Sale	19.48	50,000	974,000		Aug 05 05:02 PM
Adair Jason	Chief Business Officer	Jul 28 '25	Sale	19.54	454	8,871	193,180	Jul 30 04:31 PM
Boyle Dana	Chief Accounting Officer	Jul 28 '25	Sale	19.54	1,063	20,771	186,105	Jul 30 04:30 PM
Saggar Rajeev	Chief Medical Officer	Jul 21 '25	Sale	14.54	2,526	36,728	268,887	Jul 23 04:30 PM
Schundler Russell	General Counsel	Jul 14 '25	Sale	14.28	7,836	111,898	577,977	Jul 15 04:36 PM
Saggar Rajeev	Chief Medical Officer	Jul 14 '25	Sale	14.28	5,327	76,070	271,413	Jul 15 04:36 PM
Moomaw Scott	Chief Commercial Officer	Jul 14 '25	Sale	14.28	4,797	68,501	223,231	Jul 15 04:35 PM
Krepp Sarah	Chief Human Resource Officer	Jul 14 '25	Sale	14.28	2,673	38,170	142,499	Jul 15 04:35 PM
Kaseta Michael	CFO and COO	Jul 14 '25	Sale	14.28	11,580	165,362	406,412	Jul 15 04:34 PM
JEFFS ROGER	Chief Executive Officer	Jul 14 '25	Sale	14.28	20,252	289,199	1,038,560	Jul 15 04:33 PM
JEFFS ROGER	Chief Executive Officer	Jul 14 '25	Sale	14.28	20,252	289,199	1,038,560	Jul 15 04:33 PM
Boyle Dana	Chief Accounting Officer	Jul 14 '25	Sale	14.28	1,193	17,036	187,168	Jul 15 04:30 PM
Adair Jason	Chief Business Officer	Jul 14 '25	Sale	14.28	2,576	36,785	193,634	Jul 15 04:30 PM
Schundler Russell	General Counsel	Jun 04 '25	Sale	16.97	8,460	143,566	582,054	Jun 05 04:20 PM
Moomaw Scott	Chief Commercial Officer	Jun 04 '25	Sale	16.97	6,656	112,952	224,921	Jun 05 04:20 PM
Saggar Rajeev	Chief Medical Officer	Jun 04 '25	Sale	16.97	7,597	128,921	273,209	Jun 05 04:19 PM
JEFFS ROGER	Chief Executive Officer	Jun 04 '25	Sale	16.97	30,610	519,452	1,044,979	Jun 05 04:18 PM
Kaseta Michael	CFO and COO	Jun 04 '25	Sale	16.97	14,777	250,766	412,164	Jun 05 04:18 PM
Adair Jason	Chief Business Officer	Jun 04 '25	Sale	16.97	3,597	61,041	193,735	Jun 05 04:15 PM
Schundler Russell	General Counsel	Jun 02 '25	Sale	16.74	923	15,451	571,722	Jun 03 04:49 PM
Moomaw Scott	Chief Commercial Officer	Jun 02 '25	Sale	16.74	581	9,726	216,038	Jun 03 04:47 PM
Kaseta Michael	CFO and COO	Jun 02 '25	Sale	16.74	859	14,380	397,800	Jun 03 04:45 PM
Adair Jason	Chief Business Officer	Jun 02 '25	Sale	16.74	451	7,550	184,961	Jun 03 04:44 PM
Adair Jason	Chief Business Officer	Apr 28 '25	Sale	14.24	455	6,479	183,849	Apr 30 04:15 PM
Saggar Rajeev	Chief Medical Officer	Apr 21 '25	Sale	13.67	2,450	33,492	263,152	Apr 23 04:15 PM
Schundler Russell	General Counsel	Apr 14 '25	Sale	13.57	5,964	80,931	570,301	Apr 16 05:06 PM
JEFFS ROGER	Chief Executive Officer	Apr 14 '25	Sale	13.57	14,130	191,744	1,006,420	Apr 16 05:05 PM
Moomaw Scott	Chief Commercial Officer	Apr 15 '25	Sale	13.57	3,406	46,219	214,744	Apr 16 05:04 PM
Kaseta Michael	CFO and COO	Apr 14 '25	Sale	13.57	8,283	112,400	396,315	Apr 16 05:03 PM
Saggar Rajeev	Chief Medical Officer	Apr 14 '25	Sale	13.57	3,714	50,399	265,602	Apr 16 05:02 PM
Adair Jason	Chief Business Officer	Apr 14 '25	Sale	13.57	1,856	25,186	184,304	Apr 15 09:12 PM
Schundler Russell	General Counsel	Mar 03 '25	Sale	15.45	930	14,368	576,265	Mar 04 04:32 PM
Moomaw Scott	Chief Commercial Officer	Mar 03 '25	Sale	15.45	592	9,146	218,150	Mar 04 04:31 PM
Kaseta Michael	CFO and COO	Mar 03 '25	Sale	15.45	874	13,503	404,598	Mar 04 04:31 PM
Adair Jason	Chief Business Officer	Mar 03 '25	Sale	15.45	451	6,968	182,254	Mar 04 04:30 PM

AXSM

Axsome Therapeutics Inc

LQDA

Liquidia Corp

Upgrade your FINVIZ experience